A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME
A Phase 2, Multicenter, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Two Doses of ENN0403 in Subjects With Diabetic Macular Edema (DME)
This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050027
- Shijiazhuang People's Hospital
-
Xingtai、Hebei、中国、054001
- Hebei Eye Hospital
-
-
Henan
-
Zhengzhou、Henan、中国、450015
- Zhengzhou Second Hospital
-
-
Shandong
-
Weifang、Shandong、中国、261041
- Affiliated Hospital of Shandong Second Medical University
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200040
- Shanghai Eye Disease Prevention and Treatment Center
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030002
- Shanxi Eye Hospital
-
Xi’an、Shanxi、中国、710002
- Xian No.1 Hospital
-
-
Sichuan
-
Chengdu、Sichuan、中国、610075
- Hospital of Chengdu University of TCM
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300384
- Tianjin Medical University Eye Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Provide written informed consent;
- Aware of the entire study process and requirements, understands the importance of medication compliance and completing all assessments on time throughout the study, and agrees to strictly follow the protocol and study procedures, including restrictions on drug combination during the study;
- Diagnosis of type 1 or type 2 diabetes mellitus and HbA1c≤10.0% with regular use hypoglycemic drugs and stable glycemic control 1 month before screening (at the discretion of the investigator);
- The decrease of BCVA is mainly caused byDiabetic Macular Edema in the study eye;
- BCVA letter score of ≤ 73 (Snellen 20/40) and ≥ 24 (Snellen 20/320) at screening visit and at baseline. If both eyes meet the inclusion criteria, the study eye will be determined by the investigator from a medical perspective. ( If both eyes meet the inclusion criteria,the eye with poor baseline vision will be selected as the study eye; If the BCVA number is the same, choose the eye with the thicker CRT as the study eye) ;
- Optical Coherence Tomography (OCT) foveal CRT at screening measuring ≥300 μm.
Exclusion Criteria:
- Study eye with any eye disease or medical history other than DME that causes or may cause irreversible vision loss;
- Study eye had glaucoma filtration surgery in the past or may have the surgery during the study;
- Study eye had previously undergone vitreoretinal surgery;
- Study eye received intraocular hormone drugs within 6 months prior to baseline or periocular or systemic hormone drugs within 3 months prior to baseline;
- Any eye received intraocular injection of VEGF within 3 months prior to baseline;
- History of idiopathic or autoimmune uveitis in any eye;
- Uncontrolled glaucoma in any eye (defined as IOP ≥25 mmHg after treatment with anti-glaucoma drugs)
- History of allergy to the investigational drug or any ingredient, or to any ingredient used during the treatment;
- Use of any other investigational drug or device within 3 months or 5 half-lives prior to baseline (whichever is longer);
- Other factors considered inappropriate for inclusion in this study at the discretion of the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ENN0403低剂量治疗臂
|
ENN0403 capsules will be orally administered once a day for 12 weeks. |
|
实验性的:ENN0403 高剂量治疗臂
|
ENN0403 capsules will be orally administered once a day for 12 weeks. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第 12 周时中央视网膜厚度 (CRT) 较基线的变化
大体时间:第12周
|
第12周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
第 4、8 和 12 周时最佳矫正视力 (BCVA) 较基线的变化
大体时间:第 4、8、12 周
|
第 4、8、12 周
|
|
第 4 周和第 8 周 CRT 相对基线的变化
大体时间:第 4、8 周
|
第 4、8 周
|
|
眼部和非眼部 TEAE 和 SAE 的发生率
大体时间:12周
|
12周
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ENN0403-P2-CN-03
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.